NEW YORK (GenomeWeb News) – Response Genetics today announced the execution of a provider contract with Blue Cross and Blue Shield of Illinois, providing the health plan's 7.4 million members coverage for the Los Angeles-based molecular diagnostics firm's tests.

Response Genetics offers molecular predictive tests for lung, colon, gastric, and melanoma cancers, as well as tests for detecting EGFR, KRAS, and other mutations. Its tests, the firm said, help physicians determine which treatments may be best for each individual patient.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

Fareed Zakaria writes that instead of focusing solely on STEM-related courses, students would do well to pursue the liberal arts if they want to be technology innovators.

A Harvard Business Review study found four major patterns of gender biases and added that black and Latina scientists further had to navigate racial stereotypes.